Nang Kuang Pharmaceutical Valuation
Is 1752 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1752 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1752 (NT$45.2) is trading below our estimate of fair value (NT$45.62)
Significantly Below Fair Value: 1752 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1752?
Other financial metrics that can be useful for relative valuation.
What is 1752's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | NT$4.56b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.3x |
Enterprise Value/EBITDA | 11.1x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 1752's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 15.1x | ||
8279 Syngen BiotechLtd | 14.7x | 8.1% | NT$4.0b |
1762 Chunghwa Chemical Synthesis & Biotech | 13.5x | n/a | NT$3.6b |
1777 SYN-TECH Chem. & Pharm | 15.6x | n/a | NT$3.9b |
1734 Sinphar PharmaceuticalLtd | 16.5x | n/a | NT$6.2b |
1752 Nang Kuang Pharmaceutical | 23x | n/a | NT$4.6b |
Price-To-Earnings vs Peers: 1752 is expensive based on its Price-To-Earnings Ratio (23x) compared to the peer average (15.1x).
Price to Earnings Ratio vs Industry
How does 1752's PE Ratio compare vs other companies in the TW Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 1752 is good value based on its Price-To-Earnings Ratio (23x) compared to the TW Pharmaceuticals industry average (25.1x).
Price to Earnings Ratio vs Fair Ratio
What is 1752's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 23x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1752's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.